Literature DB >> 20669002

[Progressive supranuclear palsy: living environment of the patients in Germany].

M Hensler1, S Paul, C Abright, S Lorenzl.   

Abstract

The living environment of patients suffering from progressive supranuclear palsy (PSP) has attracted little interest so far. The aim of this study was to record environmental factors and patient care structures of PSP patients in Germany. In light of this aim 100 questionnaires consisting of 28 questions were distributed in the journal PSP-Rundschau (PSP Review) in February 2009. Up to August 2009, 69 completed questionnaires had been received for evaluation. The main results were a long period up to diagnosis (3.33 ± 2.5 years) and early clinical symptoms noted by many patients which could be used for the differential diagnosis between PSP and Parkinson's disease. In 87% of the cases the patients were cared for by relatives at home mostly without professional nursing home care.It is hoped that this investigation has shed more insight into the life and disease-related symptoms of patients with PSP and can provide valuable information for the understanding and treatment of this devastating disease.

Entities:  

Mesh:

Year:  2011        PMID: 20669002     DOI: 10.1007/s00115-010-3076-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  28 in total

1.  Social Security Disability Insurance (SSDI) in Parkinson's disease.

Authors:  T A Zesiewicz; A Patel-Larson; R A Hauser; K L Sullivan
Journal:  Disabil Rehabil       Date:  2007-07-03       Impact factor: 3.033

2.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

3.  Amitriptyline in the management of progressive supranuclear palsy.

Authors:  J N Kvale
Journal:  Arch Neurol       Date:  1982-06

4.  Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy.

Authors:  D Testa; D Monza; M Ferrarini; P Soliveri; F Girotti; G Filippini
Journal:  Neurol Sci       Date:  2001-06       Impact factor: 3.307

5.  Donepezil in the treatment of progressive supranuclear palsy.

Authors:  G Fabbrini; P Barbanti; V Bonifati; C Colosimo; M Gasparini; N Vanacore; G Meco
Journal:  Acta Neurol Scand       Date:  2001-02       Impact factor: 3.209

6.  A clinical rating scale for progressive supranuclear palsy.

Authors:  Lawrence I Golbe; Pamela A Ohman-Strickland
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

Review 7.  Progressive supranuclear palsy: where are we now?

Authors:  David J Burn; Andrew J Lees
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

8.  The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  E R Maher; A J Lees
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

Review 9.  Progressive supranuclear palsy. Clinical and pharmacologic update.

Authors:  J Jankovic
Journal:  Neurol Clin       Date:  1984-08       Impact factor: 3.806

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more
  3 in total

1.  The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study.

Authors:  Demetris Pillas; Alexander Klein; Teresa Gasalla; Andreja Avbersek; Alexander Thompson; Jack Wright; Jennifer Mellor; Anna Scowcroft
Journal:  Front Neurol       Date:  2022-07-04       Impact factor: 4.086

2.  Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.

Authors:  Michael Gold; Stefan Lorenzl; Alistair J Stewart; Bruce H Morimoto; David R Williams; Illana Gozes
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-09       Impact factor: 2.570

3.  The "Surprise Question" in Neurorehabilitation-Prognosis Estimation by Neurologist and Palliative Care Physician; a Longitudinal, Prospective, Observational Study.

Authors:  Markus Ebke; Andreas Koch; Kim Dillen; Ingrid Becker; Raymond Voltz; Heidrun Golla
Journal:  Front Neurol       Date:  2018-09-24       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.